ALC-2206

ALC-2206 is a generic small molecule drug candidate developed by Korea Arlico Pharm, a South Korean pharmaceutical company. It is currently positioned within the company's cardiovascular system pipeline. As a generic therapeutic, ALC-2206 is designed to be a bioequivalent version of an established reference cardiovascular medication, likely targeting chronic conditions such as hypertension or dyslipidemia. While the specific active pharmaceutical ingredient (API) has not been publicly disclosed in the company's high-level pipeline documentation, the project is part of a broader series of cardiovascular generic developments (including ALC-2207 and ALC-2208) aimed at expanding Korea Arlico Pharm's portfolio in the domestic market.